Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | CASR | P41180 | 4/20 | 0.37 |
| ▸ | CCR5 | P51681 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096793 | 0.89 | CCR5 (0.37) | CASRCCR5 | |
| SCHEMBL1096487 | 0.88 | CASR (0.40) | NPC1CASRCCR5MAPTSTAT1 | |
| SCHEMBL1096227 | 0.86 | CCR5 (0.36) | CASRCCR5CYP2D6KMT2A | |
| SCHEMBL1096451 | 0.85 | CASR (0.36) | CASRCCR5CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL16274939 | 0.83 | CCR5 (0.44) | NPC1CCR5RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL1105784 | 0.82 | CASR (0.45) | NPC1CASRCYP2D6 | |
| SCHEMBL1096965 | 0.82 | CASR (0.39) | CASRCCR5CYP2D6 | |
| Hydrochloric Acid SCHEMBL1096704 | 0.82 | CASR (0.46) | NPC1CASRCYP2D6 | |
| SCHEMBL1095287 | 0.81 | ESR1 (0.37) | CASRCCR5ALDH1A1HSD17B10 | |
| SCHEMBL1095286 | 0.81 | NPY2R (0.42) | NPC1MAPTSTAT1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2085383-A1 | PIPERIDINE DERIVATIVES OR SALTS THEREOF | Astellas Pharma Inc. (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | NPC1 2162/4885CASR 1/4885CCR5 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.